ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
Status:
RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer.
The names of the study drugs involved in this study are:
* Azenosertib (a type of WEE1 inhibitor)
* Carboplatin (a type of platinum compound)
* Pembrolizumab (a type of monoclonal antibody)
Phase:
PHASE1
Details
Lead Sponsor:
Filipa Lynce, MD
Collaborators:
Merck Sharp & Dohme LLC Zentalis Pharmaceuticals
Treatments:
Carboplatin Immunoglobulin G pembrolizumab Platinum